Suppression of Alzheimer's Disease-Related Phenotypes by Geranylgeranylacetone in Mice

HANDLE オープンアクセス

抄録

Amyloid-beta peptide (A beta) plays an important role in the pathogenesis of Alzheimer's disease (AD). A beta is generated by the secretase-mediated proteolysis of beta-amyloid precursor protein (APP), and cleared by enzyme-mediated degradation and phagocytosis. Transforming growth factor (TGF)-beta 1 stimulates this phagocytosis. We recently reported that the APP23 mouse model for AD showed fewer AD-related phenotypes when these animals were crossed with transgenic mice expressing heat shock protein (HSP) 70. We here examined the effect of geranylgeranylacetone, an inducer of HSP70 expression, on the AD-related phenotypes. Repeated oral administration of geranylgeranylacetone to APP23 mice for 9 months not only improved cognitive function but also decreased levels of A beta, A beta plaque deposition and synaptic loss. The treatment also up-regulated the expression of an A beta-degrading enzyme and TGF-beta 1 but did not affect the maturation of APP and secretase activities. These outcomes were similar to those observed in APP23 mice genetically modified to overexpress HSP70. Although the repeated oral administration of geranylgeranylacetone did not increase the level of HSP70 in the brain, a single oral administration of geranylgeranylacetone significantly increased the level of HSP70 when A beta was concomitantly injected directly into the hippocampus. Since geranylgeranylacetone has already been approved for use as an anti-ulcer drug and its safety in humans has been confirmed, we propose that this drug be considered as a candidate drug for the prevention of AD.

収録刊行物

  • Plos one

    Plos one 8 (10), e76306-, 2013-10-01

    Public library science

詳細情報 詳細情報について

  • CRID
    1050001339014529408
  • NII論文ID
    120005365906
  • HANDLE
    2115/54117
  • ISSN
    19326203
  • 本文言語コード
    en
  • 資料種別
    journal article
  • データソース種別
    • IRDB
    • CiNii Articles

問題の指摘

ページトップへ